Sonolisib/PX-866 is an improved semi-synthetic analog of Wortmannin, which is an oral, irreversible pan-PI3K inhibitor that had demonstrated significant anti-tumor effect in squamous cell carcinoma of head and neck (SCCHN) patients with PI3K mutation [156]. The gene discussed is PIK3CD; the disease is neoplasm.